April 26 (FAP)-the US Food and Drug Administration (FDA) agreed to speed up the approval of Bojian's drugs for the treatment of ALS, a rare disease that affects motor neurons, and asked Bojian to further study its experimental drug tofersen. (.)

April 26 (FAP)-the US Food and Drug Administration (FDA) agreed to speed up the approval of Bojian's drugs for the treatment of ALS, a rare disease that affects motor neurons, and asked Bojian to further study its experimental drug tofersen. (Bloomberg)